Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

This study found that topical cetirizine 1% significantly improved hair density and diameter in patients with androgenetic alopecia, with patients tolerating the treatment well.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

This source reports that clascoterone cream, a topical androgen receptor inhibitor, has shown effectiveness in treating facial acne vulgaris in patients 12 and older, with clinical trials indicating a favorable safety profile compared to systemic treatments, and potential for broader dermatological applications.

This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

This study found that differently charged micelles influence the acid-base equilibria of cetirizine by altering its ionization constants, indicating potential interactions with biomolecules of various charges under physiological conditions.

In this study, researchers analyzed social media data to assess the comparative safety of arthritis medications, finding increased odds of herpes zoster and perforated bowel with certain therapies. Social media posts expressed more safety concerns than favorable opinions about drug safety.

This article discusses the challenges in treating hidradenitis suppurativa, highlighting that adalimumab is currently the only FDA-approved treatment, and reports no clinical results.

This review summarizes updated US prescribing information for teriflunomide in relapsing multiple sclerosis, highlighting its efficacy in reducing lesion activity and relapse rates but noting potential adverse effects such as headache and diarrhea.

This study found that applying a 1% cetirizine solution daily for 16 weeks resulted in a statistically significant increase in hair count among men with androgenetic alopecia, although improvements in global photographs were less pronounced, highlighting the need for larger studies to confirm these findings.

This case report describes a 21-year-old woman with progressive alopecia areata who experienced hair regrowth while treated with tocilizumab for posterior uveitis, suggesting the potential for this drug to affect hair loss and regrowth by disrupting interleukin-6 signaling.

This study found that econazole nitrate delivered via MPEG-dihexPLA micelles significantly increased skin deposition compared to Pevaryl® cream, potentially enhancing drug bioavailability and clinical efficacy.

In this study, compound zishenqing formula combined with standard medications improved symptoms and immune indices in female SLE patients, with a lower occurrence of side effects compared to standard medications alone.

An arthritis drug helped a person with severe hair loss regrow their hair.

This article discusses the role of insulin resistance in cardiovascular risk and suggests that lifestyle changes may be more beneficial than metformin in managing polycystic ovary syndrome; it reports no new clinical results.

This study concluded that clomiphene citrate is generally preferred over metformin for inducing ovulation in obese women with PCOS, despite low-quality evidence indicating metformin may be superior to placebo for live births.

This letter to the editor discusses the use of topical cetirizine 1% for treating androgenetic alopecia but reports no new clinical outcomes.

This study reports that ZD1839 (Iressa), an anticancer drug, was associated with acneiform eruptions and hair growth abnormalities due to its inhibition of epidermal growth factor receptor signaling in the skin.

In this study, hydroxychloroquine, nitazoxanide, and ivermectin demonstrated similar efficacy for overall clinical outcomes in COVID-19 when administered early with azithromycin, vitamins, and supplements, with nitazoxanide showing the strongest antiviral activity and safety profile among the three.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

This case report suggests that clomiphene citrate can effectively restore fertility in some men with a long history of anabolic steroid abuse, though individual responses to treatment vary.

This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.

This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.

This abstract describes the initial success of intralesional cidofovir for SCC treatment and states that it has not shown systemic toxicity, but it does not report new clinical trial results.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

In this study, tacrolimus-based treatment was found to result in fewer overall side effects compared to cyclosporine among Yemeni kidney transplant patients, although tacrolimus was associated with a higher incidence of diabetes.